FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2968045260> ?p ?o ?g. }

• W2968045260 endingPage "854" @default.
• W2968045260 startingPage "845" @default.
• W2968045260 abstract "Background Bronchiectasis guidelines recommend long-term macrolide treatment for patients with three or more exacerbations per year without Pseudomonas aeruginosa infection. Randomised controlled trials suggest that long-term macrolide treatment can prevent exacerbations in adult patients with bronchiectasis, but these individual studies have been too small to do meaningful subgroup analyses. We did a systematic review and individual patient data (IPD) meta-analysis to explore macrolide benefit in subpopulations, including those in which macrolide therapy is not currently recommended. Methods We searched MEDLINE, Embase, the Cochrane Central Register of Controlled Trials, and Web of Science from Jan 1, 2000, to Sept 30, 2018, to identify double blind, randomised, placebo-controlled trials of macrolide antibiotics in adult patients with bronchiectasis. We applied no language restrictions. Randomised controlled trials were eligible if treatment was defined a priori as long term and had a primary or secondary outcome of bronchiectasis exacerbations. Studies in patients with cystic fibrosis bronchiectasis were excluded. The primary outcome of the meta-analysis was frequency of exacerbations requiring treatment with antibiotics. Secondary endpoints were time to first exacerbation, change in quality of life according to the St George's Respiratory Questionnaire (SGRQ), and change in FEV1. IPD meta-analysis was done using fixed effects models adjusting for age, sex, FEV1, and trial. We did prespecified subgroup analyses for each of the primary and secondary endpoints using one-step meta-analysis only. Subgroups were defined by age, sex, previous exacerbation frequency, smoking status, inhaled corticosteroid use at baseline, body-mass index at baseline, cause, C-reactive protein at baseline, baseline FEV1 percentage of predicted, SGRQ total score, and Pseudomonas aeruginosa in sputum culture at baseline. The meta-analysis is registered with the PROSPERO international register of systematic reviews, number CRD42018102908. Findings Of 234 identified studies, we included three randomised controlled trials, and IPD was obtained for 341 participants. Macrolide antibiotics reduced the frequency of exacerbations (adjusted incidence rate ratio [IRR] 0·49, 95% CI 0·36 to 0·66; p<0·0001). We also found that macrolide treatment improved the time to first exacerbation (adjusted hazard ratio 0·46, 0·34 to 0·61; p<0·0001) and was associated with improved quality of life measured by the SGRQ (mean improvement 2·93 points, 0·03 to 5·83; p=0·048). Macrolides were not associated with a significant improvement in FEV1 (67 mL at 1 year, −22 to 112; p=0·14). Effect estimates in prespecified subgroup analyses revealed a reduced frequency of exacerbations in all prespecified subgroups, including a high level of benefit in patients with P aeruginosa infection (IRR 0·36, 0·18–0·72; p=0·0044) and in patients with one to two exacerbations per year (0·37, 0·16–0·88; p=0·025). Studies were rated as low risk of bias across all domains. Interpretation Long-term macrolide treatment significantly reduces the frequency of exacerbations in patients with bronchiectasis, with similar benefits observed in all subgroups based on patient characteristics. This finding suggests that macrolides might be considered in patients in whom macrolides are not indicated according to the current guidelines, particularly if alternative approaches to reduce exacerbations have been unsuccessful. However, downsides of long-term macrolide treatment must also be taken into account. Funding European Respiratory Society." @default.
• W2968045260 created "2019-08-22" @default.
• W2968045260 creator A5004924208 @default.
• W2968045260 creator A5008754128 @default.
• W2968045260 creator A5011506804 @default.
• W2968045260 creator A5020542518 @default.
• W2968045260 creator A5035517850 @default.
• W2968045260 creator A5049094804 @default.
• W2968045260 creator A5050636729 @default.
• W2968045260 creator A5055927650 @default.
• W2968045260 creator A5056681502 @default.
• W2968045260 creator A5064519407 @default.
• W2968045260 creator A5077869936 @default.
• W2968045260 date "2019-10-01" @default.
• W2968045260 modified "2023-10-13" @default.
• W2968045260 title "Long-term macrolide antibiotics for the treatment of bronchiectasis in adults: an individual participant data meta-analysis" @default.
• W2968045260 cites W1974498819 @default.
• W2968045260 cites W1993060410 @default.
• W2968045260 cites W2037017598 @default.
• W2968045260 cites W2050118439 @default.
• W2968045260 cites W2059378575 @default.
• W2968045260 cites W2090648579 @default.
• W2968045260 cites W2096373158 @default.
• W2968045260 cites W2108506420 @default.
• W2968045260 cites W2112215977 @default.
• W2968045260 cites W2118796703 @default.
• W2968045260 cites W2120959053 @default.
• W2968045260 cites W2128677706 @default.
• W2968045260 cites W2129241942 @default.
• W2968045260 cites W2144443028 @default.
• W2968045260 cites W2161284151 @default.
• W2968045260 cites W2163467593 @default.
• W2968045260 cites W2168697989 @default.
• W2968045260 cites W2169216429 @default.
• W2968045260 cites W2276030464 @default.
• W2968045260 cites W2409855484 @default.
• W2968045260 cites W2605691061 @default.
• W2968045260 cites W2610600568 @default.
• W2968045260 cites W2616404591 @default.
• W2968045260 cites W2623856550 @default.
• W2968045260 cites W2752498201 @default.
• W2968045260 cites W2782093117 @default.
• W2968045260 cites W2782364381 @default.
• W2968045260 cites W2784506567 @default.
• W2968045260 cites W2788969512 @default.
• W2968045260 cites W2792967594 @default.
• W2968045260 cites W2891610856 @default.
• W2968045260 cites W2892241519 @default.
• W2968045260 cites W2916004124 @default.
• W2968045260 cites W4210754331 @default.
• W2968045260 doi "https://doi.org/10.1016/s2213-2600(19)30191-2" @default.
• W2968045260 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31405828" @default.
• W2968045260 hasPublicationYear "2019" @default.
• W2968045260 type Work @default.
• W2968045260 sameAs 2968045260 @default.
• W2968045260 citedByCount "93" @default.
• W2968045260 countsByYear W29680452602019 @default.
• W2968045260 countsByYear W29680452602020 @default.
• W2968045260 countsByYear W29680452602021 @default.
• W2968045260 countsByYear W29680452602022 @default.
• W2968045260 countsByYear W29680452602023 @default.
• W2968045260 crossrefType "journal-article" @default.
• W2968045260 hasAuthorship W2968045260A5004924208 @default.
• W2968045260 hasAuthorship W2968045260A5008754128 @default.
• W2968045260 hasAuthorship W2968045260A5011506804 @default.
• W2968045260 hasAuthorship W2968045260A5020542518 @default.
• W2968045260 hasAuthorship W2968045260A5035517850 @default.
• W2968045260 hasAuthorship W2968045260A5049094804 @default.
• W2968045260 hasAuthorship W2968045260A5050636729 @default.
• W2968045260 hasAuthorship W2968045260A5055927650 @default.
• W2968045260 hasAuthorship W2968045260A5056681502 @default.
• W2968045260 hasAuthorship W2968045260A5064519407 @default.
• W2968045260 hasAuthorship W2968045260A5077869936 @default.
• W2968045260 hasBestOaLocation W29680452602 @default.
• W2968045260 hasConcept C126322002 @default.
• W2968045260 hasConcept C142724271 @default.
• W2968045260 hasConcept C168563851 @default.
• W2968045260 hasConcept C177713679 @default.
• W2968045260 hasConcept C1862650 @default.
• W2968045260 hasConcept C187212893 @default.
• W2968045260 hasConcept C187960798 @default.
• W2968045260 hasConcept C204787440 @default.
• W2968045260 hasConcept C27081682 @default.
• W2968045260 hasConcept C2777014857 @default.
• W2968045260 hasConcept C2777714996 @default.
• W2968045260 hasConcept C2778155338 @default.
• W2968045260 hasConcept C2779379686 @default.
• W2968045260 hasConcept C2780206985 @default.
• W2968045260 hasConcept C501593827 @default.
• W2968045260 hasConcept C71924100 @default.
• W2968045260 hasConcept C86803240 @default.
• W2968045260 hasConcept C89423630 @default.
• W2968045260 hasConcept C95190672 @default.
• W2968045260 hasConceptScore W2968045260C126322002 @default.
• W2968045260 hasConceptScore W2968045260C142724271 @default.
• W2968045260 hasConceptScore W2968045260C168563851 @default.
• W2968045260 hasConceptScore W2968045260C177713679 @default.
• W2968045260 hasConceptScore W2968045260C1862650 @default.

• next